openPR Logo
Press release

Global Peptide Therapeutics Market & Clinical Pipeline Insight 2026

12-12-2019 12:26 PM CET | Health & Medicine

Press release from: PNS Pharma

The global peptide drug market is expected to surpass US$ 50 Billion by 2026 as per recent report "Global Peptide Therapeutics Market & Clinical Pipeline Insight 2026" published by PNS Pharma. Report gives comprehensive insight on ongoing clinical trials of more than 800 peptide drugs across the globe. Report has more than 140 graphs and charts to represent peptide clinical trials data, available drug dosage, price insight and patent information.

For Report Sample Contact: or call +91-11-47067990

Report Table of Contents

1. Introduction to Peptide Therapeutics
1.1 Overview & Historical Development
1.2 Why We Need Peptide Therapeutics?

2. Foundation of Peptide Therapeutics
2.1 Screening of Novel Peptide Molecules
2.2 Production of Therapeutic Peptides
2.3 Regulation over Peptide Therapeutics

3. Key Aspects in Peptide Drug Development
3.1 Approaches to Overcome Peptide Associated Limitations
3.1.1 Terminal Protection
3.1.2 Non-Chemical Modifications
3.1.3 Synthetic Amino Acid Substitution & Backbone Modification
3.1.4 Computational Modifications for Improving Aqueous Solubility & Membrane
3.2 High-Throughput Screening (HTS) for New Peptide Entity

4. Peptide Therapeutics over Traditional Molecules
4.1 Peptides v/s Biological Proteins
4.2 Peptides v/s Small Molecules

5. Global Peptide Therapeutics Market Scenario
5.1 Market Overview
5.2 Market by Region
5.2.1 North America
5.2.2 Europe
5.2.3 Asia
5.3 Peptide Therapeutic Market Segmentation by Application
5.3.1 Peptides in Imaging
5.3.2 Peptides in Diseases
5.4 Market by Route of Administration
5.4.1 Current Scenerio
5.4.2 Current Trends over Approved Peptide Products

6. Global Peptide Oncology Thereupetics Market Scenario
6.1 Market Overview
6.2 Peptide Oncology Drug Market - Regional Segmentation

7. Cancer Peptides Drug Cost, Dosage & Patent Insight
7.1 Firmagon (Degarelix)
7.2 Mepact (Mifamurtide)
7.3 Zoladex (Goserelin)
7.4 Eligard (Leuprolide)
7.5 Lupron (Leuprolide Acetate)
7.6 Plenaxis (Abarelix)
7.7 Trelstar (Treptorelin)
7.8 Decapeptyl SR (Treptorelin Acetate or Pamoate)
7.9 Octreotide
7.10 Sandostatin (Octeriotide Acetate)
7.11 Velcade (bortizomib)
7.12 Cosmegen (Dactinomycin)
7.13 Somatuline Depot (lanreotide)
7.14 Suprefact (Buserelin)
7.15 Ninlaro (Ixazomib)
7.16 Kyprolis (Carfilzomib)
7.17 Gonax (Degarelix Acetate)

8. Peptide Therapeutics in Cardiovascular Disease
8.1 Overview to Global Cardiovascular Diseases Burden
8.2 Peptide Drugs in Cardiovascular Diseases – Availability & Cost Analysis
8.3 Cardiac Peptide Therapeutics – Sales Analysis

9. Peptide Therapeutics in Metabolic Disorder
9.1 Overview to Global Metabolic Disorders Burden
9.2 Peptide Drugs for Metabolic Disorders – Availability, Cost & Dosage Analysis
9.3 Market of Metabolic Peptides

10. Peptide Therapeutics For Infections
10.1 Overview to Infectious Diseases
10.2 Global - HIV Infection Burden
10.3 Commercially Available Anti-Infective Peptide Drugs
10.4 Anti-Infectious Peptide Drugs - Regional & Sales Analysis

11. Peptide Therapeutics aganist CNS Disorders
11.1 Overview to CNS Disorders
11.2 Approaches for Developing Neuropeptide Drugs
11.3 Opportunities for Neuropeptide Drug Market

12. Global Peptides Drug Clinical Insight by Type
12.1 Dipeptides
12.2 Cyclic Peptides
12.3 Depsipeptides
12.4 Glucagon-Like Peptide
12.5 Glycopeptides
12.6 Insulin
12.7 Lipopeptides
12.8 Natriuretic Peptides
12.9 Neuropeptides
12.10 Oligopeptides
12.11 Opioid Peptides
12.12 Peptide Homone
12.13 Peptides
12.14 Peptide Fragments
12.15 Peptide Vaccine
12.16 Multiple Peptides

13. Global Peptide Drug Market Dynamics – Challenges & Drivers
13.1 Global Peptide Drug Market Drivers
13.2 Challenges for Global Peptide Drug Market

14. Global Peptide Therapeutics Market Future Panorama
14.1 Future Trends in Peptide Therapeutics
14.2 Peptides Therapeutics Market Opportunities

15. Oligopeptides Clinical Pipeline By Company, Indication & Phase
15.1 Preclinical
15.2 Phase-I
15.3 Phase-I/II
15.4 Phase-II
15.5 Phase-III
15.6 Preregistration
15.7 Registered
15.8 Marketed

16. Insulin Clinical Pipeline By Company, Indication & Phase
16.1 Unknown
16.2 Research
16.3 Preclinical
16.4 Clinical
16.5 Phase-I
16.6 Phase-I/II
16.7 Phase-II
16.8 Phase-II/III
16.9 Phase-III
16.10 Preregistration
16.11 Registered
16.12 Marketed

17. Peptide Hormone Clinical Pipeline By Company, Indication & Phase
17.1 Unknown
17.2 Research
17.3 Preclinical
17.4 Clinical
17.5 Phase-I
17.6 Phase-I/II
17.7 Phase-II
17.8 Phase-III
17.9 Preregistration
17.10 Marketed

18. Peptide Clinical Pipeline By Company, Indication & Phase
18.1 Unknown
18.2 Research
18.3 Preclinical
18.4 Clinical
18.5 Phase-I
18.6 Phase-I/II
18.7 Phase-II
18.8 Phase-II/III
18.9 Phase-III
18.10 Preregistration
18.11 Registered
18.12 Marketed

19. Glucagon-Like Peptide Clinical Pipeline By Company, Indication & Phase
19.1 Preclinical
19.2 Clinical
19.3 Phase-I
19.4 Phase-II
19.5 Phase-III
19.6 Preregistration
19.7 Marketed

20. Glycopeptide Clinical Pipeline By Company, Indication & Phase
20.1 Preclinical
20.2 Phase-I
20.3 Phase-I/II
20.4 Marketed

21. Multiple Peptide Clinical Pipeline By Company, Indication & Phase
21.1 Research
21.2 Preclinical
21.3 Phase-I
21.4 Phase-II
21.5 Phase-II/III
21.6 Phase-III
21.7 Preregistration
21.8 Registered
21.9 Marketed

22. Peptide vaccine Clinical Pipeline By Company, Indication & Phase
22.1 Preclinical
22.2 Phase-I
22.3 Phase-I/II
22.4 Phase-II
22.5 Phase-III
22.6 Registered
22.7 Marketed

23. Cyclic Peptide Clinical Pipeline By Company, Indication & Phase
23.1 Unknown
23.2 Research
23.3 Preclinical
23.4 Phase-I
23.5 Phase-II
23.6 Phase-II/III
23.7 Phase-III
23.8 Preregistration
23.9 Registered
23.10 Marketed

24. Peptide Fragment Clinical Pipeline By Company, Indication & Phase
24.1 Research
24.2 Preclinical
24.3 Phase-I
24.4 Phase-I/II
24.5 Phase-II
24.6 Phase-II/III
24.7 Preregistration
24.8 Registered
24.9 Marketed

25. Dipeptide Clinical Pipeline By Company, Indication & Phase
25.1 Preclinical
25.2 Phase-I
25.3 Phase-I/II
25.4 Phase-II
25.5 Phase-III
25.6 Registered
25.7 Marketed

26. Opioid peptide Clinical Pipeline By Company, Indication & Phase
26.1 Phase-I/II
26.2 Phase-II
26.3 Preregistration
26.4 Registered
26.5 Marketed

27. Depsipeptide Clinical Pipeline By Company, Indication & Phase
27.1 Preclinical
27.2 Phase-I
27.3 Registered
27.4 Marketed

28. Natriuretic Peptide Clinical Pipeline By Company, Indication & Phase
28.1 Research
28.2 Phase-II
28.3 Phase-III
28.4 Marketed

29. Neuropeptide Clinical Pipeline By Company, Indication & Phase
29.1 Research
29.2 Preclinical
29.3 Phase-I
29.4 Phase-I/II
29.5 Phase-II
29.6 Marketed

30. Pituitary Gonadotropin Clinical Pipeline By Company, Indication & Phase
30.1 Unknown
30.2 Preclinical
30.3 Phase-I
30.4 Phase-II
30.5 Phase-III
30.6 Marketed

31. Lipopeptide Clinical Pipeline By Company, Indication & Phase
31.1 Research
31.2 Preclinical
31.3 Phase-II
31.4 Phase-III

32. Peptide Aptamer Clinical Pipeline By Company, Indication & Phase
32.1 Preclinical
32.2 Phase-I
32.3 Phase-I/II
32.4 Phase-III

33. Competitive Landscape
33.1 Amgen
33.2 Amylin Pharmaceuticals
33.3 Apitope Technology
33.4 BioPartners
33.5 BiondVax Pharmaceuticals Ltd
33.6 Boehringer Ingelheim
33.7 Circassia
33.8 Corden Pharma (Peptisyntha)
33.9 Eli Lily
33.10 Galena Biopharmaceuticals
33.11 GlaxoSmithKline
33.12 Hyperion Therapeutics
33.13 ImmunoCellular Therapeutics
33.14 Ipsen
33.15 Lonza
33.16 Merck
33.17 NovoNordisk
33.18 Par Pharmaceuticals
33.19 PeptiDream
33.20 Roche
33.21 Sanofi
33.22 Tarix Pharmaceuticals

Dr. Mukherjee Nagar, India - 110009

PNS Pharma is a pioneer in offering exclusive research reports for the pharmaceuticals industry. PNS Pharma offers Syndicated Research Reports on Drug Pipeline and Company Pipeline Analysis. These reports include comprehensive information related to the development of various drugs across clinical pipeline. Further, the reports include details on the originator, Owner, License, Chemical Formula, Patent Information, Phase of development, and Phase of development by country for each specific drug. The reports on company pipeline include all the drugs developed by particular companies across different therapeutic segments and phases and in different countries.

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global Peptide Therapeutics Market & Clinical Pipeline Insight 2026 here

News-ID: 1878649 • Views: 241

More Releases from PNS Pharma

Global Gene Therapy Market To Witness Positive Outlook With More Than USD 8 Bill …
Gene therapy process has successfully gained popularity among the researchers all around the globe. Since its discovery, the primary driver of the market of the gene therapy process is considered to be its ability to alter the cause of the disease at the molecular level and that too precisely than the other available technologies. The technological advancements and the development in the gene delivery systems have developed a bright scope
Global Gene Therapy Market Size Sales To Surpass USD 8 Billion By 2026
" Global Gene Therapy Market Opportunity & Clinical Trials Insight 2026" Report Highlights: o Global Gene Therapy market Opportunity: > USD 8 Billion o Global Gene Therapy Pipeline:: > 1000 In Trials o Commercially Available Gene Therapies: 11 o US & Europe Are Key Markets Download Report: 1. Introduction to Gene Therapy 1.1 Gene Therapy: An Overview 1.2 History of Development 2. Gene Therapy & its Impact on Genetic Alterations 2.1 Gene Therapy as a Mastermind of Genetic Revolution
Global Breast Cancer Drug Market & Clinical Trial Insight 2025
" Global Breast Cancer Drug Market & Clinical Trial Insight 2025" Report Highlights: • Global Breast Cancer Drug Market: US$ 40 Billion Opportunity • Global Breast Cancer Drug Clinical Pipeline: More Than 550 Drugs • Marketed Breast Cancer Drugs: More Than 90 Drugs • Comprehensive Clinical Insight & Patent Information • Drug Trials, Pricing, Dosage, Cancer Prevalence Insight: 130 Graphs/Charts Download Report: The applied science research has marked tremendous advancements in cutting off the epidemic cancer scenarios all around the
Global Peptide Drug Therapeutics Market Size Will Reach US$ 65 Billion by 2026
“Global Peptide Therapeutics Market & Clinical Pipeline Insight 2026” report highlights: • Global Peptide Therapeutics Market Opportunity: US$ 65 Billion • Peptide Therapeutics Market Opportunity: US$ 22 Billion • Insight Peptide Drugs in Clinical Trials: 807 Peptides Drugs • Clinical & Patent Insight on 197 Marketed Peptides • Peptide Clinical Pipeline Is Dominated by Cyclic Peptides: 46 Peptides • Peptides Clinical Trials Insight by Phase, Indication & Company • Future Peptide Therapeutics Market Outlook Download Report: “Global Peptide Therapeutics Market

All 5 Releases

More Releases for Phase

PHASE-XS – Access To Life Changing Biosimilars
Biopharmaceutical is one of the fastest growing industries with addition of numerous biologics that provide novel treatment modalities for life-threatening and rare diseases. Biologics are produced from living organisms through unique manufacturing and purification processes. It includes a wide variety of products such as vaccines, blood, blood components, cells, allergens, genes, tissues, and recombinant proteins that are derived from human, animal or microorganisms by using biotechnological procedures. Some examples for
Global Phase Locked Loops Market Research Report
This report studies the global Phase Locked Loops market status and forecast, categorizes the global Phase Locked Loops market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in United States, Europe, China, Japan, South Korea and Taiwan and other regions Get sample copy of the report: Table of Contents: Table of Contents Global Phase Locked Loops Market Research Report 2018 1 Phase Locked Loops Market Overview
2026 Global Pharmacovigilance Market Growth Analysis by Clinical Trials Like Pre …
Global Pharmacovigilance Market 2018 report includes extensive Market analysis and industry landscape along with SWOT analysis and PESTEL analysis of the important vendors. The analysis is conducted with a blend of secondary and primary advice for inputs from participants in the industry. Pharmacovigilance industry report covers the prospects of Women’S Health P oducts in the forecast period of 2018-2026 and the scenario. Growing prevalence of adverse reactions caused by drugs, has
MAAT Inaugurates Versatile Phase Shifter
Company announces release of a digital recreation of Roger Schult’s analog hardware MAAT Incorporated, a manufacturer of exceptional performance professional audio solutions, today announced the release of RSPhaseShifter version 1.0, a digital implementation of the Roger Schult/German Audio Lab’s Phase Shifter 500 Series W2324 hardware. The cross–platform plug–in creates a high quality, phase shifted version of a monaural or stereo input. Available in formats for all major DAWs (Digital Audio Workstations), RSPhaseShifter
Pre-Registration, Filing Rejected/Withdrawn, Phase Iii, Phase Ii, Phase I, Precl …
"Migraine - Pipeline Review, H2 2016" The Report covers current Market Trends, Worldwide Analysis, Global Forecast, Review, Share, Size, Growth, Effect. Description- Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Migraine Pipeline Review, H2 2016, provides an overview of the Migraine (Central Nervous System) pipeline landscape. Migraine is a disorder characterized by repeated attacks of severe headache. A migraine headache causes throbbing or pulsating pain, usually on only one side of
Epsilon Award 2008 - Nomination phase has started
The Epsilon Award is a combination of Excellency, craftsmanship and visionary ability. These are characteristics of an outstanding programmer and a piece of true software art. And you can now send your application for nomination for this prestigious award of our software industry. Please read all details and find the relevant signup link on the webportal of the European Software Conference 2008, taking place in Berlin on November 8